<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48774">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149628</url>
  </required_header>
  <id_info>
    <org_study_id>3-2013-0098</org_study_id>
    <nct_id>NCT02149628</nct_id>
  </id_info>
  <brief_title>The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide</brief_title>
  <official_title>The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide in Patients Undergoing Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Robot assisted laparoscopic radical prostatectomy(Robot-LRP) requires pneumoperitoneum and
      trendelenburg position which result in oxidative stress and inflammatory response.

      Propofol is well known to reduce those responses during anesthesia. Therefore, we try to
      figure out the efficacy of propofol to reduce oxidative stress, inflammatory response  and
      increase the nitric oxide activity during robot-LRP compared to that of desflurane.

      To investigate the oxidative stress, malondialdehyde will be measured. As inflammatory
      markers, interleukin-1β, interleukin-6, tumor necrosis factor-α will be measured. Nitric
      oxide will be measured as well.

      Secondarily, kidney protection effect of propofol over desflurane will be compared.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>changes of serum malondialdehyde, Interleukin-1β, interleukin-6, tumor necrotic factor-α, nitric oxide during operation</measure>
    <time_frame>100 min after pneumoperitoneum, 10 min after decompression</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>kidney function after anesthesia</measure>
    <time_frame>1 day after operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>measure creatinine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>desflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>propofol infusion with target-controlled infusion(TCI) device guided by BIS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <arm_group_label>propofol</arm_group_label>
    <other_name>fresofol, 2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <arm_group_label>desflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing robot-assisted laparoscopic radical prostatectomy under general
             anesthesia

        Exclusion Criteria:

          -  chronic renal failure ( estimated glomerular filtration rate &lt;60 mL/min/1.73m2)

          -  allergy to propofol, nuts

          -  on diuretics, vitamin C or vitamin E within 5 days before surgery

          -  Body mass index &gt; 30 kg/m2

          -  older than 70 years

          -  who cannot read the patient consent form
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goun Roh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University, Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Woo Han, MD, PhD</last_name>
    <phone>82-2-2019-3529</phone>
    <email>hanesth@yuhs.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Goun Roh, MD</last_name>
    <phone>82-2-2019-6095</phone>
    <email>gone7968@yuhs.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yonsei University, Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Woo Han, MD,PhD</last_name>
      <phone>82-2-2019-3529</phone>
      <email>hanesth@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Goun Roh, MD</last_name>
      <phone>82-2-2019-6095</phone>
      <email>gone7968@yuhs.ac</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
